Cargando…

Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines

Detalles Bibliográficos
Autores principales:	Çuburu, Nicolas, Finn, Olivera J., Van Der Burg, Sjoerd H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171359/ https://www.ncbi.nlm.nih.gov/pubmed/35686125 http://dx.doi.org/10.3389/fimmu.2022.924099

Ejemplares similares

Premalignant Lesions as Targets for Cancer Vaccines
por: Finn, Olivera J.
Publicado: (2003)

Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer
por: Ma, Peiwen, et al.
Publicado: (2019)

Editorial: Biomarkers in the era of cancer immunotherapy: zooming in from the periphery to the tumor microenvironment
por: Charo, Jehad, et al.
Publicado: (2023)

The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy
por: Verdegaal, Els M. E., et al.
Publicado: (2017)

Redirecting the focus of cancer immunotherapy to premalignant conditions
por: Young, M. Rita I.
Publicado: (2017)

Editorial: Rising stars in cancer immunity and immunotherapy 2022
por: Goyvaerts, Cleo, et al.
Publicado: (2023)

Cell Fate Reprogramming in the Era of Cancer Immunotherapy
por: Zimmermannova, Olga, et al.
Publicado: (2021)

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
por: Zachariah, Nadia Nocera, et al.
Publicado: (2021)

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
por: Deng, Zhuoya, et al.
Publicado: (2022)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

Editorial: “Cancer Immunotherapy: Lights and Shadows”
por: Barrio, María Marcela, et al.
Publicado: (2015)

Editorial: Targeting Metabolism in Cancer Immunotherapy
por: Roszik, Jason, et al.
Publicado: (2018)

Editorial: NKT Cells in Cancer Immunotherapy
por: Webb, Tonya J., et al.
Publicado: (2020)

Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer
por: Garcia-Mouronte, Emilio, et al.
Publicado: (2023)

Editorial: NK Cell-Based Cancer Immunotherapy
por: Borrego, Francisco, et al.
Publicado: (2016)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Erratum: Editorial: NKT Cells in Cancer Immunotherapy
Publicado: (2020)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

Editorial: Nanobody-based cancer immunotherapy and immunoimaging
por: Jafari, Mahdie, et al.
Publicado: (2023)

Editorial: Extracellular traps in cancer immunity and immunotherapy
por: Rahat, Michal A., et al.
Publicado: (2023)

Editorial: Adenosine pathways in cancer immunity and immunotherapy
por: Fu, Junjiang, et al.
Publicado: (2023)

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
por: Wirth, Thomas C., et al.
Publicado: (2017)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
por: Peyraud, Florent, et al.
Publicado: (2022)

Editorial: Myeloid Derived Suppressor Cells as Disease Modulators
por: Finn, Olivera J., et al.
Publicado: (2020)

Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
por: Martin, Francisco, et al.
Publicado: (2022)

Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy
por: Feron, Olivier, et al.
Publicado: (2023)

Editorial: Novel biomarkers for predicting response to cancer immunotherapy
por: Huangfu, Shuchen, et al.
Publicado: (2023)

Editorial: Emerging talents in cancer immunity and immunotherapy: 2022
por: Maeurer, Markus
Publicado: (2023)

Editorial: Translation of genetically engineered T cells in cancer immunotherapy
por: Voss, Ralf-Holger, et al.
Publicado: (2023)

Editorial: Dual role of inflammatory mediators in cancer immunotherapy
por: Wang, Xiaoli, et al.
Publicado: (2023)

Editorial: Influenza Virus Vaccines and Immunotherapies
por: Kumar, Arun, et al.
Publicado: (2015)

Indomethacin Treatment of Mice with Premalignant Oral Lesions Sustains Cytokine Production and Slows Progression to Cancer
por: Johnson, Sara D., et al.
Publicado: (2016)

Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning
por: Ye, Zilan, et al.
Publicado: (2022)

The challenge of making the right choice: patient avatars in the era of cancer immunotherapies
por: Kayser, Charlotte, et al.
Publicado: (2023)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy
por: Rangel, Roberto, et al.
Publicado: (2022)

Inflammatory microenvironment in gastric premalignant lesions: implication and application
por: Zhang, Shengxiong, et al.
Publicado: (2023)

Future Challenges in Cancer Resistance to Immunotherapy
por: van Elsas, Marit J., et al.
Publicado: (2020)

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
por: Paiardini, Mirko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8dla3s8inufjboo2e38a42182d